This is a contrast between ProQR Therapeutics N.V. (NASDAQ:PRQR) and Intec Pharma Ltd. (NASDAQ:NTEC) based on their analyst recommendations, profitability, institutional ownership, risk, dividends, earnings and valuation. The two companies are Biotechnology and they also compete with each other.
Demonstrates ProQR Therapeutics N.V. and Intec Pharma Ltd. earnings per share, gross revenue and valuation.
Table 2 demonstrates the return on equity, net margins and return on assets of ProQR Therapeutics N.V. and Intec Pharma Ltd.
ProQR Therapeutics N.V. and Intec Pharma Ltd. Recommendations and Ratings are available on the next table.
ProQR Therapeutics N.V.’s upside potential is 149.50% at a $37.5 average target price.
Institutional Insider Ownership
ProQR Therapeutics N.V. and Intec Pharma Ltd. has shares held by institutional investors as follows: 63.5% and 40.62%. ProQR Therapeutics N.V.’s share held by